Patents by Inventor Margret Schottelius
Margret Schottelius has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944691Abstract: The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit hCXCR4 and mCXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.Type: GrantFiled: September 11, 2019Date of Patent: April 2, 2024Assignee: TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Theresa Osl, Hans-Jürgen Wester, Margret Schottelius, Tobias Kapp, Horst Kessler
-
Patent number: 11639373Abstract: The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit CXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.Type: GrantFiled: September 11, 2019Date of Patent: May 2, 2023Assignee: TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Theresa Osl, Hans-Jürgen Wester, Margret Schottelius
-
Publication number: 20220040339Abstract: The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit hCXCR4 and mCXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.Type: ApplicationFiled: September 11, 2019Publication date: February 10, 2022Inventors: Theresa OSL, Hans-Jürgen WESTER, Margret SCHOTTELIUS, Tobias KAPP, Horst KESSLER
-
Publication number: 20220041674Abstract: The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit CXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.Type: ApplicationFiled: September 11, 2019Publication date: February 10, 2022Inventors: Theresa OSL, Hans-Jürgen WESTER, Margret SCHOTTELIUS
-
Publication number: 20210338841Abstract: This invention relates to compounds of formula I or Ia: (I) (Ia). Y is EuK, —EuAF, —EuPG, -L-EuE; Z is a chelating moiety; and the other substituents are as defined herein. Also provided are formulations comprising such a compound, as well as methods of imaging or methods for the treatment of cancer comprising use of such a compound or formulation.Type: ApplicationFiled: October 11, 2019Publication date: November 4, 2021Inventors: Fijs W.B. VAN LEEUWEN, Hans-Jurgen WESTER, Tessa BUCKLE, Danny VAN WILLIGEN, Margret SCHOTTELIUS, Saskia KROPF
-
Patent number: 10919938Abstract: The present invention, among others, relates to a compound having a structure according to formula (I) or a pharmaceutically acceptable salt thereof, wherein Xaa1 are the iodo-substituted or methyl-substituted amino acids D- and L-Tyr, iodo-substituted or methyl- substituted D- and L-homotyrosine, iodo-substituted or methyl-substituted D- and L-Phe, iodo-substituted or methyl-substituted D- and L-p-OH-phenylglycine, and iodo-substituted or methyl-substituted D- or L-Trp, Xaa2 to Xaa4 are independently of each other, an optionally N-alkylated natural or unnatural amino acid, R is H or methyl, L is a linker moiety, Ar is a spacer comprising an aromatic moiety, and D comprises, preferably is i) a combination of an organic complexation agent and a radioactive or a detectable label; or ii) a radioactive or a detectable label, an organic complexation agent or an active substance, said active substance particularly being selected from cytotoxic agents, lipids, sugars, sugar conjugates, sugar derivatives, proteins anType: GrantFiled: June 6, 2014Date of Patent: February 16, 2021Assignee: TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Hans-Jürgen Wester, Margret Schottelius, Theresa Osl, Andreas Poschenrieder, Marina Willibald
-
Publication number: 20180037608Abstract: The present invention, among others, relates to a compound having a structure according to formula (I) or a pharmaceutically acceptable salt thereof, wherein Xaa1 are the iodo-substituted or methyl-substituted amino acids D- and L-Tyr, iodo-substituted or methyl- substituted D- and L-homotyrosine, iodo-substituted or methyl-substituted D- and L-Phe, iodo-substituted or methyl-substituted D- and L-p-OH-phenylglycine, and iodo-substituted or methyl-substituted D- or L-Trp, Xaa2 to Xaa4 are independently of each other, an optionally N-alkylated natural or unnatural amino acid, R is H or methyl, L is a linker moiety, Ar is a spacer comprising an aromatic moiety, and D comprises, preferably is i) a combination of an organic complexation agent and a radioactive or a detectable label; or ii) a radioactive or a detectable label, an organic complexation agent or an active substance, said active substance particularly being selected from cytotoxic agents, lipids, sugars, sugar conjugates, sugar derivatives, proteins anType: ApplicationFiled: June 6, 2014Publication date: February 8, 2018Applicant: TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Hans-Jürgen WESTER, Margret SCHOTTELIUS, Theresa OSL, Andreas POSCHENRIEDER, Marina WILLIBALD
-
Patent number: 9266924Abstract: The present invention, among others, relates to a compound having a structure according to formula (I) or a pharmaceutically acceptable salt thereof, wherein Xaa1 to Xaa4 are independently of each other, an optionally N-alkylated natural or unnatural amino acid, R is H or methyl, L is a linker moiety, Ar is a spacer comprising an aromatic moiety, and D comprises, preferably is i) a combination of an organic complexation agent and a detectable label; or ii) a detectable label, an organic complexation agent or an active substance, said active substance particularly being selected from cytotoxic agents, lipids, sugars, sugar conjugates, sugar derivatives, proteins and combinations thereof, with the proviso that -L-Ar-D does not comprise a 18F-benzoyl residue.Type: GrantFiled: April 20, 2011Date of Patent: February 23, 2016Assignee: TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Oliver Demmer, Horst Kessler, Hans-Jürgen Wester, Margret Schottelius, Ingrid Dijkgraaf, Andreas Konard Buck
-
Patent number: 8575100Abstract: Improved sst-receptor binding peptidic ligands for diagnostic and therapeutic applications in nuclear medicine are provided. The improved ligands contain either natural or unnatural amino acids or peptidomimetic structures that are modified at either the N-terminal or the C-terminal end or at both termini, a carbohydrate unit and a chelator or prosthetic group to provide a complexation of a radioisotope binding or holding the radioisotope. The sst- or SSTR-receptor binding peptidic ligands may also contain one or more multifunctional linker units optionally coupling the peptide, and/or the sugar moiety and/or the chelator and/or the prosthetic group. Upon administering the ligand to a mammal through the blood system the ligand provides improved availability, clearance kinetics, sst-receptor targeting and internalization over the non-carbohydrated ligands.Type: GrantFiled: September 10, 2009Date of Patent: November 5, 2013Assignee: Mallinckrodt LLCInventors: Hans-Jurgen Wester, Margret Schottelius, Markus Schwaiger
-
Publication number: 20130129622Abstract: The present invention, among others, relates to a compound having a structure according to formula (I) or a pharmaceutically acceptable salt thereof, wherein Xaa1 to Xaa4 are independently of each other, an optionally N-alkylated natural or unnatural amino acid, R is H or methyl, L is a linker moiety, Ar is a spacer comprising an aromatic moiety, and D comprises, preferably is i) a combination of an organic complexation agent and a detectable label; or ii) a detectable label, an organic complexation agent or an active substance, said active substance particularly being selected from cytotoxic agents, lipids, sugars, sugar conjugates, sugar derivatives, proteins and combinations thereof, with the proviso that -L-Ar-D does not comprise a 18F-benzoyl residue.Type: ApplicationFiled: April 20, 2011Publication date: May 23, 2013Applicant: TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Oliver DEMMER, Horst KESSLER, Hans-Jürgen WESTER, Margret SCHOTTELIUS, Ingrid DIJKGRAAF, Andreas Konard BUCK
-
Publication number: 20090324497Abstract: Improved sst-receptor binding peptidic ligands for diagnostic and therapeutic applications in nuclear medicine are provided. The improved ligands contain either natural or unnatural amino acids or peptidomimetic structures that are modified at either the N-terminal or the C-terminal end or at both termini, a carbohydrate unit and a chelator or prosthetic group to provide a complexation of a radioisotope binding or holding the radioisotope. The sst- or SSTR-receptor binding peptidic ligands may also contain one or more multifunctional linker units optionally coupling the peptide, and/or the sugar moiety and/or the chelator and/or the prosthetic group. Upon administering the ligand to a mammal through the blood system the ligand provides improved availability, clearance kinetics, sst-receptor targeting and internalization over the non-carbohydrated ligands.Type: ApplicationFiled: September 10, 2009Publication date: December 31, 2009Applicant: Mallinckrodt Inc.Inventors: Hans-Jurgen Wester, Margret Schottelius, Markus Schwaiger
-
Patent number: 7589061Abstract: Improved sst-receptor binding peptidic ligands for diagnostic and therapeutic applications in nuclear medicine are provided. The improved ligands contain either natural or unnatural amino acids or peptidomimetic structures that are modified at either the N-terminal or the C-terminal end or at both termini, a carbohydrate unit and a chelator or prosthetic group to provide a complexation of a radioisotope binding or holding the radioisotope. The sst- or SSTR-receptor binding peptidic ligands may also contain one or more multifunctional linker units optionally coupling the peptide, and/or the sugar moiety and/or the chelator and/or the prosthetic group. Upon administering the ligand to a mammal through the blood system the ligand provides improved availability, clearance kinetics, sst-receptor targeting and internalization over the non-carbohydrated ligands.Type: GrantFiled: April 23, 2002Date of Patent: September 15, 2009Assignee: Mallinckrodt Inc.Inventors: Hans-Jurgen Wester, Margret Schottelius, Markus Schwaigen